ArticleFamilial cancer2015
Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.
Article in Familial cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.Journal of cancer research and clinical oncology · 2021Pooled it
- Endometrial thickness among BRCA mutation carriers undergoing prophylactic oophorectomy.Familial cancer · 2025Article
- The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.Journal of cancer research and clinical oncology · 2024Review
- Type I or Type II Endometrial Carcinoma? Role of BRCA1 Immunohistochemistry.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Basic knowledge for counseling patients undergoing risk-reducing salpingo-oophorectomy.Obstetrics & gynecology science · 2024Article
- Endometrial Cancer Risk Among GermlineJCO precision oncology · 2023Review
- Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?Hormones (Athens, Greece) · 2023Review
- The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.International journal of molecular sciences · 2023Review
- Endometrial Cancer and BRCA Mutations: A Systematic Review.Journal of clinical medicine · 2022Review
- Review
- Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.Medical oncology (Northwood, London, England) · 2021Article
- BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.European journal of cancer (Oxford, England : 1990) · 2020Article
- Recurrent uterine serous carcinoma with a germline pathogenicGynecologic oncology reports · 2020Article
- Cancer susceptibility gene mutations in type I and II endometrial cancer.Gynecologic oncology · 2019Article
- Review
- Association of Combined Estrogen-Progestogen and Progestogen-Only Contraceptives with the Development of Cancer.The Linacre quarterly · 2018Review
- Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.JAMA oncology · 2018Article
- Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Review
- Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.Familial cancer · 2016Review
- Metastasis of Pregnancy-Associated Breast Cancer (Suspected to Be Hereditary Breast and Ovarian Cancer) to the Brain, Diagnosed at 18 Weeks' Gestation: A Case Report and Review of the Literature.Case reports in obstetrics and gynecology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 5 countries.
Funding
Abstract
BRCA mutation carriers may use tamoxifen for breast cancer prevention or treatment. Hormone replacement therapy is often prescribed after surgical menopause and oral contraceptives are recommended for ovarian cancer prevention. The objective of this study was to assess the impact of these medications and other risk factors on endometrial cancer risk in BRCA carriers. Women with a BRCA1 or BRCA2 mutation were identified from a registry of mutation carriers. Cases were 83 women who had a diagnosis of endometrial cancer. Controls were 1027 matched women who did not develop endometrial cancer and who had an intact uterus. All women completed a baseline questionnaire, which included questions about ages at menarche and menopause, oral contraceptive use, hormone replacement therapy use, hysterectomy, oophorectomy, breast cancer history and tamoxifen use. We estimated the odds ratio associated with each risk factor in a multivariate analysis. No differences were found between cases and controls in terms of age at menarche, BMI, smoking, or oral contraceptive use. In a multivariate analysis, for women taking estrogen-only hormone replacement therapy, the odds ratio was 0.23 (95% CI 0.03-1.78, p = 0.16), and for women taking progesterone-only hormone replacement therapy the odds ratio was 6.91 (95% CI 0.99-98.1, p = 0.05). The adjusted odds ratio for endometrial cancer associated with a history of tamoxifen use was 3.50 (95% CI 1.51-8.10, p = 0.003). The observed increased risk of endometrial cancer associated with progesterone-only therapy merits further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.